Open Text Corporation vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Open Text Corporation trades at $23.25 (market cap $5.62B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.34 (market cap $2.28B). The key difference: Open Text Corporation is far larger — about 2.5× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Open Text Corporation pays a 4.84% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| OTEX | SLS | |
|---|---|---|
Market Cap | $5.62B | $2.28B |
Volume | 1,217,244 | 3,128,960 |
Sector | Technology | Health |
52-Week High | $39.69 | $15.46 |
52-Week Low | $20.01 | $1.39 |
Typical Hold Time | 23 Days | — |
Enterprise Value | $10.64B | $2.15B |
Dividend Yield | 4.84% | — |
Signals from Pluang's Aura AI — not financial advice
OpenText (OTEX) trades at $23.14, up 1.89% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with a P/E of 8.97 and consistent earnings beats, including Q2 2026 EPS of $1.23 beating expectations by 20.6%. Recent debt refinancing activities and a strategic AI partnership with Cohere highlight management's focus on growth and financial flexibility.
OTEX presents a compelling value opportunity with discounted valuation multiples and improving cloud momentum, though elevated debt levels and competitive pressures remain key risks. Analyst consensus targets $28.30 (22% upside) with 42% buy ratings, suggesting cautious optimism for the software company's transformation efforts.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →